Arcutis Biotherapeutics Inc. (ARQT)
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARQT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.33B
- P/E (TTM)
- 119.82
- Forward P/E
- 24.09
- EPS (TTM)
- $0.22
- Dividend yield
- None
- 52-week range
- 19.30 – 34.80
- Day range
- 26.29 – 27.46
- Volume / Avg
- 1.29M / 2.58M
- Beta
- —
- Shares outstanding
- 126.46M
52-week range
ARQT stock today
Arcutis Biotherapeutics (ARQT) closed at $26.36 on Nov 20, down 2.98% (-$0.81), versus the S&P 500's 3.70% decline. Trading was light, with 1.29M shares changing hands, about 50% of the average daily volume. At this level, ARQT sits in the middle of its 52-week range of $19.30 to $34.80: 24.3% below the high, set on Nov 4, 2026 and 36.6% above the low.
ARQT is down 9.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.6%. Arcutis Biotherapeutics trades at 119.8x its trailing twelve-month earnings per share of $0.22. Its forward P/E of 24.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Arcutis Biotherapeutics
Company profileArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Todd Franklin Watanabe M.A.
- Headquarters
- Westlake Village, CA
- Employees
- 354
- IPO year
- 2020
- Website
- arcutis.com
Financial highlights
Full financialsIn fiscal 2025, Arcutis Biotherapeutics generated $376.1 million in revenue, up 91.3% from fiscal 2024, its 4th consecutive year of revenue growth. Arcutis Biotherapeutics reported a net loss of $16.1 million, compared with a loss of $140.0 million a year earlier. Gross margin was 90.2% (flat year over year) and operating margin -3.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $376.07M | $196.54M | $59.61M | $3.69M | $0 |
| Growth | +91.34% | +229.74% | +1517.09% | — | — |
| Net income | $-16.14M | $-140.04M | $-262.14M | $-311.46M | $-206.36M |
| EPS (diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$40.38+53.19%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.06 vs $0.17
- Surprise
- -64.71%
ARQT news
All ARQT news- Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific MeetingGlobeNewswire
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Arcutis (ARQT) Q3 2026 Earnings Call TranscriptNasdaqARQT, BRK.B
- Arcutis Biotherapeutics, Inc. Reports Q3 2026 Net Product Revenues of $143.9 million and Raises Full-Year Guidance to $535 million–$545 millionNasdaq
- Arcutis Biotherapeutics GAAP EPS of $0.06 misses by $0.10, revenue of $143.9M beats by $1.31MSeeking Alpha
- Arcutis Announces Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Arcutis Biotherapeutics, Inc. Appoints Dr. Robert Scott to Board of DirectorsNasdaq
- Arcutis Appoints Rob Scott, MD to Board of DirectorsGlobeNewswire
Arcutis Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs ARQT |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs ARQT |
| IRONDisc Medicine Inc. | 75.14 | -1.27% | $3.42B | vs ARQT |
| ELVNEnliven Therapeutics Inc. | 46.53 | +0.26% | $3.42B | vs ARQT |
| PBLSParabilis Medicines Inc. | 27.44 | -0.67% | $3.44B | vs ARQT |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs ARQT |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs ARQT |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs ARQT |
Indexes, lists and sector
Arcutis Biotherapeutics stock FAQ
What is Arcutis Biotherapeutics's stock price today?
ARQT last traded at $26.36 as of Nov 20, 4:00 PM EST, down 2.98% on the day. Prices are delayed at least 15 minutes.
What is ARQT's P/E ratio?
ARQT trades at a trailing P/E ratio of 119.82 and a forward P/E of 24.09.
Who is Arcutis Biotherapeutics's CEO?
Mr. Todd Franklin Watanabe M.A. is the chief executive officer of Arcutis Biotherapeutics Inc., which has about 354 employees.
What is the ARQT 52-week high?
The 52-week high for ARQT is $34.80 and the 52-week low is $19.30. The stock is currently 24.3% below its high.